Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. Pfizer has denied access to Paxlovid for an independent RCT
[Ledford ] .
[Hoertel ] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
0
0.5
1
1.5+
All studies 39% 22
40,041
Improvement, Studies, Patients Relative Risk Mortality 63% 11
24,101
Ventilation 30% 3
4,954
ICU admission 31% 3
4,319
Hospitalization 47% 10
22,956
Progression 41% 2
4,040
Recovery 5% 2
142
Cases 37% 1
1,971
Viral clearance 17% 7
2,491
RCTs 69% 3
5,201
RCT mortality 90% 2
3,230
Peer-reviewed 41% 13
6,705
Prophylaxis 37% 1
1,971
Early 44% 21
38,162
Late 32% 1
307
Paxlovid for COVID-19 c19 early.org/pl Feb 2023Favors paxlovid Favors control after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW) 19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+ 79%
0.21 [0.05-0.82]
death
Arbel 40-64 -32%
1.32 [0.16-10.8]
death
Najjar-Debbiny 46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson 71%
0.29 [0.12-0.71]
death
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES) 79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu 12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM) 95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong 15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhou (PSM) 73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM) 66%
0.34 [0.22-0.52]
death
Schwartz (PSW) 50%
0.50 [0.41-0.61]
death
Pandit 1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Bajema (PSM) 58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW) -4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans 41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.11, I2 = 85.4%, p < 0.0001
Early treatment 44%
0.56 [0.47-0.68]
45/13,783
301.6/24,379
44% improvement Li 32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment 32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement Pfizer (DB RCT) 37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis 37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement All studies 39%
0.61 [0.53-0.72]
85/14,852
431.6/25,588
39% improvement Paxlovid COVID-19 studies c19 early.org/pl Feb 2023Tau2 = 0.07, I2 = 80.4%, p < 0.0001
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW) 19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+ 79%
0.21 [0.05-0.82]
death
Arbel 40-64 -32%
1.32 [0.16-10.8]
death
Najjar-Debbiny 46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson 71%
0.29 [0.12-0.71]
death
Li (ES) 79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu 12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM) 95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Zhong 15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhou (PSM) 73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM) 66%
0.34 [0.22-0.52]
death
Schwartz (PSW) 50%
0.50 [0.41-0.61]
death
Pandit 1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Bajema (PSM) 58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW) -4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans 41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.18, I2 = 86.2%, p < 0.0001
Early treatment 49%
0.51 [0.40-0.65]
45/13,749
301.6/24,151
49% improvement Li 32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment 32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement Pfizer (DB RCT) 37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis 37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement All studies 43%
0.57 [0.47-0.70]
85/14,818
431.6/25,360
43% improvement Paxlovid COVID-19 studies after exclusions c19 early.org/pl Feb 2023Tau2 = 0.12, I2 = 81.5%, p < 0.0001
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 66%
0.34 [0.23-0.50]
890 (n)
890 (n)
Arbel 65+ 79%
0.21 [0.05-0.82]
Arbel 40-64 -32%
1.32 [0.16-10.8]
Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
0/576
1/569
Dryden-Peterson 71%
0.29 [0.12-0.71]
Ganatra (PSM) 95%
0.05 [0.00-0.81]
0/1,130
10/1,130
Zhou (PSM) 73%
0.27 [0.13-0.58]
7/2,808
100/10,849
Wong (PSM) 66%
0.34 [0.22-0.52]
Schwartz (PSW) 50%
0.50 [0.41-0.61]
Bajema (PSM) 58%
0.42 [0.26-0.67]
20/1,587
48.6/1,587
Tau2 = 0.04, I2 = 33.4%, p < 0.0001
Early treatment 63%
0.37 [0.29-0.48]
27/8,030
171.6/16,071
63% improvement All studies 63%
0.37 [0.29-0.48]
27/8,030
171.6/16,071
63% improvement 11 paxlovid COVID-19 mortality results c19 early.org/pl Feb 2023Tau2 = 0.04, I2 = 33.4%, p < 0.0001
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM) 3%
0.97 [0.31-3.03]
890 (n)
890 (n)
Improvement, RR [CI] Treatment Control Wong (PSM) 38%
0.62 [0.23-1.72]
Bajema (PSM) 48%
0.52 [0.12-2.16]
3/1,587
5.8/1,587
Tau2 = 0.00, I2 = 0.0%, p = 0.3
Early treatment 30%
0.70 [0.36-1.36]
3/2,477
5.8/2,477
30% improvement All studies 30%
0.70 [0.36-1.36]
3/2,477
5.8/2,477
30% improvement 3 paxlovid COVID-19 mechanical ventilation results c19 early.org/pl Feb 2023Tau2 = 0.00, I2 = 0.0%, p = 0.3
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Pfizer (DB RCT) 86%
0.14 [0.01-2.75]
0/576
3/569
Improvement, RR [CI] Treatment Control Wong (PSM) -58%
1.58 [0.95-2.63]
Bajema (PSM) 56%
0.44 [0.21-0.92]
10/1,587
22.8/1,587
Tau2 = 0.74, I2 = 78.9%, p = 0.55
Early treatment 31%
0.69 [0.21-2.27]
10/2,163
25.8/2,156
31% improvement All studies 31%
0.69 [0.21-2.27]
10/2,163
25.8/2,156
31% improvement 3 paxlovid COVID-19 ICU results c19 early.org/pl Feb 2023Tau2 = 0.74, I2 = 78.9%, p = 0.55
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 88%
0.12 [0.06-0.26]
hosp.
8/1,039
65/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 4%
0.96 [0.88-1.04]
hosp. time
890 (n)
890 (n)
Yip (PSW) 21%
0.79 [0.65-0.95]
hosp.
Arbel 65+ 73%
0.27 [0.15-0.49]
hosp.
Arbel 40-64 26%
0.74 [0.35-1.58]
hosp.
Dryden-Peterson 40%
0.60 [0.44-0.81]
hosp.
Ganatra (PSM) 56%
0.44 [0.21-0.91]
hosp.
10/1,130
23/1,130
Zhou (PSM) 84%
0.16 [0.11-0.22]
hosp.
34/2,808
752/10,849
Wong (PSM) 24%
0.76 [0.67-0.86]
hosp.
Bajema (PSM) 7%
0.93 [0.74-1.16]
hosp.
180/1,587
194.2/1,587
Tau2 = 0.16, I2 = 93.5%, p < 0.0001
Early treatment 47%
0.53 [0.39-0.71]
232/7,454
1,034.2/15,502
47% improvement All studies 47%
0.53 [0.39-0.71]
232/7,454
1,034.2/15,502
47% improvement 10 paxlovid COVID-19 hospitalization results c19 early.org/pl Feb 2023Tau2 = 0.16, I2 = 93.5%, p < 0.0001
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW) 19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+ 79%
0.21 [0.05-0.82]
death
Arbel 40-64 -32%
1.32 [0.16-10.8]
death
Najjar-Debbiny 46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson 71%
0.29 [0.12-0.71]
death
Ganatra (PSM) 95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Zhou (PSM) 73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM) 66%
0.34 [0.22-0.52]
death
Schwartz (PSW) 50%
0.50 [0.41-0.61]
death
Bajema (PSM) 58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW) -4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans 41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.07, I2 = 52.9%, p < 0.0001
Early treatment 53%
0.47 [0.38-0.58]
27/13,468
171.6/23,891
53% improvement All studies 53%
0.47 [0.38-0.58]
27/13,468
171.6/23,891
53% improvement 15 paxlovid COVID-19 serious outcomes c19 early.org/pl Feb 2023Tau2 = 0.07, I2 = 52.9%, p < 0.0001
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Zhong 15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Improvement, RR [CI] Treatment Control Pandit 1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Tau2 = 0.00, I2 = 0.0%, p = 0.49
Early treatment 5%
0.95 [0.82-1.10]
0/106
0/36
5% improvement All studies 5%
0.95 [0.82-1.10]
0/106
0/36
5% improvement 2 paxlovid COVID-19 recovery results c19 early.org/pl Feb 2023Tau2 = 0.00, I2 = 0.0%, p = 0.49
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Pfizer (DB RCT) 37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis 37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement All studies 37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement 1 paxlovid COVID-19 case result c19 early.org/pl Feb 2023Tau2 = 0.00, I2 = 0.0%, p = 0.05
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM) 28%
0.72 [0.56-0.93]
viral+
890 (n)
890 (n)
Improvement, RR [CI] Treatment Control Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES) 79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu 12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong 16%
0.84 [0.74-0.96]
viral time
106 (n)
36 (n)
Pandit 3%
0.97 [0.83-1.14]
viral+
n/a
n/a
Tau2 = 0.04, I2 = 86.1%, p = 0.00054
Early treatment 25%
0.75 [0.64-0.88]
18/1,205
130/1,378
25% improvement Li 32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment 32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement All studies 17%
0.83 [0.77-0.89]
58/1,288
260/1,602
17% improvement 8 paxlovid COVID-19 viral clearance results c19 early.org/pl Feb 2023Tau2 = 0.00, I2 = 33.4%, p < 0.0001
1 OT: comparison with other treatment Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
death
0/576
1/569
Tau2 = 0.00, I2 = 0.0%, p = 0.034
Early treatment 90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement Pfizer (DB RCT) 37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis 37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement All studies 69%
0.31 [0.06-1.53]
0/2,601
13/2,600
69% improvement 3 paxlovid COVID-19 Randomized Controlled Trials c19 early.org/pl Feb 2023Tau2 = 1.01, I2 = 45.5%, p = 0.15
Effect extraction pre-specified (most serious outcome) Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
0/576
1/569
Tau2 = 0.00, I2 = 0.0%, p = 0.034
Early treatment 90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement All studies 90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement 2 paxlovid COVID-19 RCT mortality results c19 early.org/pl Feb 2023Tau2 = 0.00, I2 = 0.0%, p = 0.034
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Wong (PSM) 66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW) 19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+ 79%
0.21 [0.05-0.82]
death
Arbel 40-64 -32%
1.32 [0.16-10.8]
death
Najjar-Debbiny 46%
0.54 [0.39-0.75]
severe case
Dryden-Peterson 71%
0.29 [0.12-0.71]
death
Li (ES) 79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu 12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM) 95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong 15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Wong (PSM) 66%
0.34 [0.22-0.52]
death
Tau2 = 0.15, I2 = 86.5%, p < 0.0001
Early treatment 50%
0.50 [0.38-0.66]
18/3,357
152/3,440
50% improvement Li 32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment 32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement All studies 41%
0.59 [0.48-0.73]
58/3,440
282/3,664
41% improvement 14 paxlovid COVID-19 peer reviewed studies c19 early.org/pl Feb 2023Tau2 = 0.08, I2 = 79.5%, p < 0.0001
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT) 96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI] Treatment Control Hammond (DB RCT) 95%
0.05 [0.00-0.89]
death
0/697
9/682
Hammond (DB RCT) 88%
0.12 [0.06-0.26]
hosp.
8/1,039
65/1,046
Hammond (DB RCT) 89%
0.11 [0.04-0.28]
hosp.
5/697
44/682
Wong (PSM) 66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Wong (PSM) 3%
0.97 [0.31-3.03]
ventilation
890 (n)
890 (n)
Wong (PSM) 43%
0.57 [0.45-0.72]
progression
890 (n)
890 (n)
Wong (PSM) 4%
0.96 [0.88-1.04]
hosp. time
890 (n)
890 (n)
Wong (PSM) 28%
0.72 [0.56-0.93]
viral+
890 (n)
890 (n)
Yip (PSW) 19%
0.81 [0.47-1.39]
death/ICU
Yip (PSW) 21%
0.79 [0.65-0.95]
hosp.
Arbel 65+ 79%
0.21 [0.05-0.82]
death
Arbel 65+ -32%
1.32 [0.16-10.8]
death
Arbel 65+ 73%
0.27 [0.15-0.49]
hosp.
Arbel 65+ 26%
0.74 [0.35-1.58]
hosp.
Arbel 40-64 -32%
1.32 [0.16-10.8]
death
Arbel 40-64 26%
0.74 [0.35-1.58]
hosp.
Najjar-Debbiny 46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT) 67%
0.33 [0.01-8.13]
death
0/576
1/569
Pfizer (DB RCT) 86%
0.14 [0.01-2.75]
ICU
0/576
3/569
Pfizer (DB RCT) 51%
0.49 [0.17-1.44]
death/hosp.
5/576
10/569
Dryden-Peterson 71%
0.29 [0.12-0.71]
death
Dryden-Peterson 44%
0.56 [0.42-0.75]
death/hosp.
Dryden-Peterson 40%
0.60 [0.44-0.81]
hosp.
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES) 79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Li (ES) 41%
0.59 [0.50-0.69]
viral time
175 (n)
224 (n)
Lu 12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM) 95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Ganatra (PSM) 39%
0.61 [0.42-0.70]
progression
89/1,130
163/1,130
Ganatra (PSM) 33%
0.67 [0.52-0.87]
progression
89/1,130
163/1,130
Ganatra (PSM) 56%
0.44 [0.21-0.91]
hosp.
10/1,130
23/1,130
Shao 20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong 15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhong 16%
0.84 [0.74-0.96]
viral time
106 (n)
36 (n)
Zhong 16%
0.84 [0.76-0.93]
viral time
106 (n)
36 (n)
Zhou (PSM) 73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Zhou (PSM) 75%
0.25 [0.10-0.61]
death
5/2,808
78/10,849
Zhou (PSM) 84%
0.16 [0.11-0.22]
hosp.
34/2,808
752/10,849
Zhou (PSM) 89%
0.11 [0.07-0.17]
hosp.
22/2,808
708/10,849
Wong (PSM) 66%
0.34 [0.22-0.52]
death
Wong (PSM) 38%
0.62 [0.23-1.72]
ventilation
Wong (PSM) -58%
1.58 [0.95-2.63]
ICU
Wong (PSM) 24%
0.76 [0.67-0.86]
hosp.
Schwartz (PSW) 50%
0.50 [0.41-0.61]
death
Schwartz (PSW) 43%
0.57 [0.48-0.68]
death/hosp.
Pandit 1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Pandit 3%
0.97 [0.83-1.14]
viral+
n/a
n/a
Pandit -171%
2.71 [0.86-8.55]
misc.
24/127
3/43
Pandit -52%
1.52 [0.55-4.25]
misc.
18/127
4/43
Bajema (PSM) 58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Bajema (PSM) 79%
0.21 [0.08-0.56]
death
5/1,587
23.6/1,587
Bajema (PSM) 48%
0.52 [0.12-2.16]
ventilation
3/1,587
5.8/1,587
Bajema (PSM) 56%
0.44 [0.21-0.92]
ICU
10/1,587
22.8/1,587
Bajema (PSM) 7%
0.93 [0.74-1.16]
hosp.
180/1,587
194.2/1,587
Bajema (PSM) 34%
0.66 [0.45-0.96]
hosp.
43/1,587
65.2/1,587
Zheng (PSW) -4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Zheng (PSW) 12%
0.88 [0.45-1.71]
death/hosp.
33/4,836
19/2,847
OT1
Evans 41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Li 32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Pfizer (DB RCT) 37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Pfizer (DB RCT) 32%
0.68 [0.46-1.00]
cases
986 (n)
985 (n)
Paxlovid COVID-19 outcomes c19 early.org/pl Feb 20231 OT: comparison with other treatment Favors paxlovid
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
